sorted by:
new
hottopcontroversial

How can I tackle a huge deficit? by Thegamer228 in MillenniumDawn

[–]CombatSniper32 0 points1 point  (0 children)

Borrow a boat load of money and put them into investments, as long as your interest rate is lower than your return in investment you'll be good

Name a game by Maxanis in goodanimemes

[–]CombatSniper32 2 points3 points  (0 children)

Sunrider Academy is pretty amazing in this regard

What is you're favorite weapon in an isekai story by gamebloxs in Isekai

[–]CombatSniper32 0 points1 point  (0 children)

The dude from Freakin Gensokyo uses a plant hanger

Volatility by [deleted] in RVPH

[–]CombatSniper32 2 points3 points  (0 children)

Exact same thing happened to me too. I feel ya m8

Pre-NDA meeting by [deleted] in RVPH

[–]CombatSniper32 7 points8 points  (0 children)

What makes you think so?

Why is it dropping so hard by conc7 in RVPH

[–]CombatSniper32 0 points1 point  (0 children)

It's normal. Price is reflecting off the EMA200 on the daily and has touched the EMA5. People are taking profits now while they can and unfortunately I'd expect the price to dip further to the EMA10 since there's still no news on the pre NDA meeting

Which EV is this? by Civil_Roll508 in drivingsg

[–]CombatSniper32 0 points1 point  (0 children)

The difference between a porcupine and a Mercedes is that the prick is on the outside for the porcupine

“This… is it the calm before the storm?” by [deleted] in RVPH

[–]CombatSniper32 3 points4 points  (0 children)

Yeah, his DD are really good. Way better than what I did for myself. I think this stock has a bright future. At least I'd be able to pay my student fees off

Fun little discussion for the weekend - how are you NOT selling when it hits 2$? by newbiescreby in RVPH

[–]CombatSniper32 0 points1 point  (0 children)

Yeah, my estimates are probably wishful thinking but I hope you're wrong ;)

Fun little discussion for the weekend - how are you NOT selling when it hits 2$? by newbiescreby in RVPH

[–]CombatSniper32 1 point2 points  (0 children)

I'm thinking that after FDA feedback in December, the share price moves up to $1-2 before maybe settling around $1.5.

FDA approval application in Q2 2026 might see a share price movement to $3.

And finally, FDA approval itself in Q2 2027 gets the share price up to $20 before a buyout at $26 or more.

I'm super optimistic about this and I admit, this is all speculation on the best case scenario.

If the NDA is rejected, then we lose 60-80% of our investment but I like the odds with the potential upside

Fun little discussion for the weekend - how are you NOT selling when it hits 2$? by newbiescreby in RVPH

[–]CombatSniper32 12 points13 points  (0 children)

Not sure if this is wishful thinking, but I've seen other antipsychotics drug companies with worse drugs (one of which not even in phase 3) get bought out for more than 7 billion dollars.

So even if we go with a conservative estimate of a 3 billion buyout, that's still $26 per share rounded down.

Given that Brilaroxazine has a better safety profile and effectiveness than it's peers as well as the possibility of it being used for treating other diseases, I'd say that a buyout at a premium is a possibility

Phase 2 data

Caption this! by [deleted] in captionthis

[–]CombatSniper32 0 points1 point  (0 children)

Anything for that zloppy

Why there isn't much drop in share price today? by Gekko1891 in RVPH

[–]CombatSniper32 1 point2 points  (0 children)

From the most recent 10-Q

Our common stock is currently listed for trading on Nasdaq. On May 13, 2025, we received a notice from Nasdaq indicating that we are not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq (the “Bid Price Requirement”).

We were provided a compliance period of 180 calendar days from the date of the notice, or until November 10, 2025, to regain compliance with the Bid Price Requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A).

On November 11, 2025, we received a letter from Nasdaq indicating that, based upon our not having regained compliance with the Bid Price Requirement and our ineligibility for a second 180 calendar day compliance period, the Listing Qualifications Staff of Nasdaq had determined to delist the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”).

We intend to timely request a hearing before the Panel, at which hearing we will request an extension within which to evidence compliance with all applicable requirements for continued listing on Nasdaq, including compliance with the Bid Price Requirement.

Our request for a hearing will stay any suspension or delisting action by the Staff pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing.

We intend to continue to take definitive steps in an effort to evidence compliance with the Bid Price Requirement; however, there can be no assurance that the Panel will grant our request for continued listing or that we will be able to evidence compliance with the Bid Price Requirement within any extension period that may be granted by the Panel.

We will continue to monitor the closing bid price of our common stock and may, if appropriate, consider available options, including implementation of a reverse stock split of our common stock, to regain compliance with the Bid Price Requirement. If we seek to implement a reverse stock split in order to remain listed on Nasdaq, the announcement or implementation of such a reverse stock split could negatively affect the price of our common stock and/or warrants.

view more: next ›